Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats

Neuroscience Letters

Volumn 438, Issue 1, 2008, Pages 10-13

  García Arencibia, Moisés ^a   Ferraro, Luca ^b   Tanganelli, Sergio ^b   Fernández Ruiz, Javier ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Basal ganglia; Cannabinoids; CB1 receptors; Glutamate; Hypokinesia; Parkinson's disease; Rimonabant

Indexed keywords

GLUTAMIC ACID; OXIDOPAMINE; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BRAIN DAMAGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; MALE; MICRODIALYSIS; MOTOR PERFORMANCE; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STRIATE CORTEX;

ANIMALS; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; EXTRACELLULAR FLUID; GLUTAMIC ACID; MALE; MICRODIALYSIS; NEURAL INHIBITION; OXIDOPAMINE; PARKINSONIAN DISORDERS; PIPERIDINES; PRESYNAPTIC TERMINALS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; SYMPATHOLYTICS; SYNAPTIC TRANSMISSION; UP-REGULATION;

EID: 43549124297     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.04.041     Document Type: Article

References (25)

1. Blandini F., Nappi G., Tassorelli C., and Martignoni E. Functional changes in the basal ganglia circuitry in Parkinson's disease. Prog. Neurobiol. 62 (2000) 63-88
2. Brotchie J.M. CB1 cannabinoid receptor signalling in Parkinson's disease. Curr. Opin. Pharmacol. 3 (2003) 54-61
3. Di Marzo V., Hill M.P., Bisogno T., Crossman A.R., and Brotchie J.M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14 (2000) 1432-1438
4. El-Banoua F., Caraballo I., Flores J.A., Galán-Rodriguez B., and Fernández-Espejo E. Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model. Neurobiol. Dis. 16 (2004) 377-385
5. Fernández-Espejo E., Caraballo I., Rodríguez de Fonseca F., El Banoua F., Ferrer B., Flores J.A., and Galán-Rodríguez B. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol. Dis. 18 (2005) 591-601
6. Fernández-Ruiz J., and González S. Cannabinoid control of motor function at the basal ganglia. In: Pertwee R.G. (Ed). Handbook of Experimental Pharmacology-168-Cannabinoids (2005), Springer-Verlag, Heidelberg, Germany 479-507
7. Ferraro L., Tomasini M.C., Gessa G.L., Bebe B.W., Tanganelli S., and Antonelli T. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb. Cortex 11 (2001) 728-733
8. González S., Scorticati C., García-Arencibia M., de Miguel R., Ramos J.A., and Fernández-Ruiz J. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res. 1073-1074 (2006) 209-219
9. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., Bernardi G., Finazzi-Agro A., and Maccarrone M. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 22 (2002) 6900-6907
10. Lastres-Becker I., Cebeira M., de Ceballos M., Zeng B.-Y., Jenner P., Ramos J.A., and Fernández-Ruiz J. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 14 (2001) 1827-1832
11. Lastres-Becker I., and Fernández-Ruiz J. An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments. Curr. Med. Chem. 13 (2006) 3705-3718
12. Maccarrone M., Gubellini P., Bari M., Picconi B., Battista N., Centonze D., Bernardi G., Finazzi-Agro A., and Calabresi P. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem. 85 (2003) 1018-1025
13. Mailleux P., and Vanderhaeghen J.J. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J. Neurochem. 61 (1993) 1705-1712
14. Meschler J.P., Howlett A.C., and Madras B.K. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology 156 (2001) 79-85
15. Meshul C.K., Emre N., Nakamura C.M., Allen C., Donohue M.K., and Buckman J.F. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 88 (1999) 1-16
16. Mesnage V., Houeto J.L., Bonnet A.M., Clavier I., Arnulf I., Cattelin F., Le Fur G., Damier P., Welter M.L., and Agid Y. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson's disease. Clin. Neuropharmacol. 27 (2004) 108-110
17. Nagatsu T., and Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J. Neural Transm. Suppl. 72 (2007) 113-120
18. Ossowska K., Konieczny J., Wardas J., Golembiowska K., Wolfarth S., and Pilc A. The role of striatal metabotropic glutamate receptors in Parkinson's disease. Amino Acids 23 (2002) 193-198
19. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, London
20. 2 receptors. Pharmacol. Ther. 74 (1997) 129-180
21. Pisani A., Fezza F., Galati S., Battista N., Napolitano S., Finazzi-Agro A., Bernardi G., Brusa L., Pierantozzi M., Stanzione P., and Maccarrone M. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann. Neurol. 57 (2005) 777-779
22. Rodríguez-Díaz M., Abdala P., Barroso-Chinea P., Obeso J., and González-Hernández T. Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease. Behav. Brain Res. 122 (2001) 79-92
23. 1 receptor mRNA levels in the caudate-putamen. Life Sci. 66 (2000) 485-494
24. Thomas B., and Beal M.F. Parkinson's disease. Hum. Mol. Genet. 16 (2007) R183-R194
25. Tuite P., and Riss J. Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin. Investig. Drugs 12 (2003) 1335-1352